Extending the 'host response' paradigm from sepsis to cardiogenic shock: evidence, limitations and opportunities

Area of Science:

• Cardiology
• Immunology
• Genomics

Background:

• Current cardiogenic shock (CS) treatments focus on cardiac output but have not improved outcomes, with static mortality rates of 30-50%.
• The pathobiology of CS, particularly the role of immune dysregulation, remains poorly understood, hindering the identification of novel therapeutic targets.
• Existing research in critical illnesses like sepsis highlights the importance of inflammation and immunity, suggesting similar mechanisms may be at play in CS.

Purpose of the Study:

• To review the rationale for investigating molecular subtypes in CS.
• To explore how high-dimensional molecular profiling, specifically leukocyte transcriptomics, can identify these subtypes.
• To determine if these molecular subtypes share biological features with sepsis and other critical illness states.

Main Methods:

• Review of existing literature on CS, inflammation, immunity, and molecular profiling techniques.
• Discussion of high-dimensional molecular profiling, including leukocyte transcriptomics.
• Analysis of potential biological similarities between CS molecular subtypes and other critical illnesses.

Main Results:

• High-dimensional molecular profiling offers a promising approach to characterize CS patient subgroups.
• Leukocyte transcriptomics can potentially identify distinct molecular subtypes within CS.
• These subtypes may share immune dysregulation mechanisms with sepsis and other critical illnesses.

Conclusions:

• Identifying molecular subtypes of CS is crucial for understanding disease heterogeneity.
• This approach can inform the design of more effective clinical trials for CS.
• Discovery of molecular subtypes may lead to novel, targeted therapies for cardiogenic shock.